Colon News and Research

RSS

Trial demonstrates improved outcomes in unsedated colonoscopy by water method

The October issue of GIE Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy (ASGE), features the results of two randomized controlled trials of unsedated colonoscopy comparing water infusion versus air insufflation to distend the colon.

30 Sep 2010

Santarus, Cosmo announce positive results from budesonide MMX Phase III study in ulcerative colitis

Santarus, Inc. and Cosmo Pharmaceuticals S.p.A. today announced positive top-line results from the Phase III clinical study conducted in the U.S. and India to evaluate the safety and efficacy of budesonide MMX® for the induction of remission of mild or moderate active ulcerative colitis. The study results show that budesonide MMX 9 mg taken once daily met the primary endpoint of superiority to placebo.

30 Sep 2010

Researchers develop C5 technology to identify CTCs in breast cancer

Researchers have identified a novel, dual-platform technology, the On-Q-ity Circulating Cancer Capture and Characterization Chip (C5), which they believe is more efficient than the commonly used single-platform device in identifying circulating tumor cells (CTCs) in breast cancer.

30 Sep 2010

Physical activity reduces risk for womb cancer

Women who exercise and keep active are around 30 per cent less likely to develop womb cancer than couch potatoes - according to a new study published in the British Journal of Cancer today.

30 Sep 2010

Some Democrats, including Reid, embrace health law as fall campaign battles continue

Politico: Some House Democrats are touting the new health law — and their support of it — as a positive in their fights to keep their seats in midterm elections this fall. The Democrats are "framing key provisions as a 'Patient's Bill of Rights.' Spurred by last week's release of a series of rigid insurance rules, the lawmakers are defying this election season's conventional wisdom placing by health care front and center." Among them are Reps. Dina Titus and Shelley Berkley or Nevada.

29 Sep 2010

Researchers identify biomarker to predict tivozanib drug resistance

Researchers believe there may be a way to predict, based on individual tumors, those patients that are more likely to respond to the investigational new drug tivozanib.

29 Sep 2010

IsoRay reports increase revenue for 2010 fiscal year

IsoRay Inc. a medical isotope company and the exclusive manufacturer of Cesium-131 used in internal radiation therapy for the treatment of lung, colon, head and neck, and prostate cancers, ocular melanoma, and other malignant disease through the use of its proprietary radioisotope technology, announced its financial results for the year ended June 30, 2010.

28 Sep 2010

Global Health Partner acquires Stockholm Gastro Center

Global Health Partner (STO:GHP) has acquired Stockholm Gastro Center, a specialist clinic with operations within medical gastroenterology and endoscopy located at Sophiahemmet in Stockholm. "The acquisition of Stockholm Gastro Center is a good complement to the obesity surgery business that we run at Kirurgkliniken and Bariatric Center Stockholm in Sophiahemmet's facilities. This is a combination of businesses that we also have at our clinics in Lund and Prague and where we see good coordination and expansion opportunities," says Per Båtelson, Global Health Partner's CEO.

28 Sep 2010

Researchers discover new signaling pathway for cell development

Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered a new cell signaling pathway that controls cell growth and development, a pathway that, when defective, helps promote the formation of several major forms of human cancer, including lymphoma and leukemia.

24 Sep 2010

NCCN launches series of guidelines on cancer treatment

Patients with cancer and their caregivers have a new resource to help them navigate the maze of treatment options that they often confront. Today at the NCCN Patient Advocacy Summit in Washington D.C., the National Comprehensive Cancer Network launched its new series of NCCN Guidelines for Patients, consumer-friendly translations of the NCCN Clinical Practice Guidelines in Oncology outlining appropriate cancer treatment.

24 Sep 2010

CAP meeting to highlight medical diagnostic procedures

New science in cancer, genetic testing, molecular diagnostics, medical ethics, and gender-based disorders will be featured topics when nearly 1,200 pathologists gather at the Hyatt Regency Chicago on September 26 - 29 for the annual scientific meeting of the College of American Pathologists (CAP).

24 Sep 2010

Raltegravir could be valid target against all Herpesviridae

Scientists at the Institute for Research in Biomedicine (IRB Barcelona) headed by the coordinator of the Structural and Computational Biology Programme, Miquel Coll, have published a new study that demonstrates that raltegravir, the drug approved in 2007 for the treatment of AIDS that is sold by Merck under the name Isentress, cancels the function of an essential protein for the replication of one kind of herpes virus.

23 Sep 2010

Oxy-Powder supplement clears clinical trials for Irritable Bowel Syndrome

The popular nutraceutical health supplement, Oxy-Powder has passed clinical trials for Irritable Bowel Syndrome (IBS) with a 99.9 percent success rate.According to the NIH, approximately 20% of Americans suffer from the symptoms of IBS, which qualifies it as one of the most common medical problems in the United States.

21 Sep 2010

Haskell completes St. John Broken Arrow Hospital

The Haskell Company announces it has completed construction on St. John Broken Arrow Hospital and its accompanying medical office building and medical campus in Broken Arrow, Okla., marking the largest design/build health care project in the company’s 45-year history.

21 Sep 2010

APC gene mutation affects DNA methylation in colon cancer: Research

Colon cancer is the second most common cancer in the United States and causes more than 50,000 deaths each year. It has been known for some time that mutations in the APC gene occur in more than 85 percent of all sporadic colon cancers. Now researchers at Huntsman Cancer Institute at the University of Utah demonstrate in a study featured today in Cell the mechanism by which mutation of the APC gene affects a cellular process known as DNA methylation.

18 Sep 2010

PAF announces expansion of Colorectal Care Line

The Patient Advocate Foundation (PAF), a national non-profit resolving patient access to health care issues, medical financial limitations, insurance denials and multiple government program enrollments, including Medicaid and Social Security Disability Income announced today a significant expansion of its Colorectal Care Line (CCL), beginning September 13, 2010.

15 Sep 2010

Study to assess impact of radiation exposure on multiple cancer risk

It is well known that exposure to radiation has multiple harmful effects - including causing cancer - but until now, it has been unclear to what extent such exposure increases a person's risk of developing more than one cancer. The first large-scale study of the relationship between radiation dose and risk of multiple cancers among atomic bomb survivors in Hiroshima and Nagasaki, Japan reveals a similar risk in the development of first and second subsequent cancers.

15 Sep 2010

NIH grants award to expand Human Microbiome Project

The National Institutes of Health has awarded a three-year, $1.1 million grant to a team of scientists at the University of Chicago and Argonne National Laboratory to develop a technology for studying the link between human health and disease and the microorganisms that reside in or on the human body.

15 Sep 2010

microRNA 451 enhances treatment response in stomach cancer patients: Research

"The high presence of microRNA 451 enhances the response to treatment with chemo-radiotherapy and increases the survival of patients with stomach cancer", explained Dr. Jesús García-Foncillas, chief researcher of the Pharmacogenomics Laboratory at the Applied Medical Research Centre (CIMA) and Director of Oncology at the University Hospital of Navarra. This was one of the results presented at the IV Congress of the Spanish Society for Pharmacogenetics and Pharmacogenomic, recently held at CIMA.

15 Sep 2010